GeneSuites: Hybrid Model Between Build & Buy
Build
In-House cGMP Build-Out
-
Capital intensive
-
Long-lead time to select site, design and build facility
-
Resource intensive to build internal construction/design team
-
Less attainable for early-stage companies
Buy
Outsource / Contract Mfg
-
Dependent on available capacity and CDMO/CMO expertise
-
Cost-effective in the short term with increasing costs over time
-
Requires tech transfer — lowering IP control
GeneSuites
A Novel Hybrid Solution
-
Multi-modal facility design and build-out by a cGMP-expert team
-
Quicker time to market, maximized IP and Process control compared to the Build model
-
Significantly lower upfront capital expenditures and risk
"GeneSuites customers can build their manufacturing team, SOPs, and all operational readiness documents because they’re making product themselves at GeneSuites; they can even participate in the commissioning and qualification process... Once they’re financially ready to transition to their next company milestone, they can pick up all the infrastructure they’ve invested in and move it to their new facility.
...it presents a huge advantage to early and mid-stage companies."
Tom Piombino, Managing Director - Americas
Conceptual GeneSuites Design
Completely isolated suites with separate HVAC and metering systems
